Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
企業コードPCRX
会社名Pacira Biosciences Inc
上場日Feb 03, 2011
最高経営責任者「CEO」Mr. Frank D. Lee
従業員数790
証券種類Ordinary Share
決算期末Feb 03
本社所在地2000 Sierra Point Parkway
都市BRISBANE
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94005
電話番号16502428052
ウェブサイトhttps://www.pacira.com/
企業コードPCRX
上場日Feb 03, 2011
最高経営責任者「CEO」Mr. Frank D. Lee
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし